You snooze, you lose: Lilly gets the jump on a rival
Eli Lilly already has the jump on Novo in obstructive sleep apnoea (OSA). Now it’s aiming to get further ahead.
To see the whole article, log in or create an account.
Fri, 13 Nov 2026
Connecting you with your industry every day
Other News
- 1 Who's stolen industry's digital innovation crown?
- 2 Industry body reboots, earning prestigious award
- 3 New Aussie Country Manager named in reshuffle
- 4 Advocacy until the very end: Her final fight for change
- 5 Is Australia's pharma workforce at breaking point?
- 6 Ex-Aussie GM lifts lid on job search